Search research articles
Contact Us
Filters
Showing results (781-790 of 932) with videos related to
Page
of 94
Sort By:
JCO Precision Oncology
|
February 16, 2022
Biomarker-Based Phase II Study of Sapanisertib (TAK-228): An mTORC1/2 Inhibitor in Patients With Refractory Metastatic Renal Cell Carcinoma
Bradley A McGregor, Wanling Xie, Elio Adib, et al.
Journal of the American College of Cardiology
|
November 26, 2015
The National Cardiovascular Data Registry Voluntary Public Reporting Program: An Interim Report From the NCDR Public Reporting Advisory Group
Gregory J Dehmer, Jonathan Jennings, Ruth A Madden, et al.
Clinical Genitourinary Cancer
|
April 5, 2026
Outcomes of Complete Responders From First-line Therapy in Metastatic Renal Cell Carcinoma in the Real World: An Analysis From the International Metastatic Renal Cell Carcinoma Database Consortium
Martin Zarba, David Maj, Razane El Hajj Chehade, et al.
Frontiers in Oncology
|
May 20, 2026
International metastatic renal cell carcinoma database consortium classification and regression tree analysis to characterize objective response rates to first line in metastatic renal cell carcinoma
Martin Zarba, Dylan O'Sullivan, David Maj, et al.
ESMO Open
|
June 20, 2024
Prognostic significance of absolute lymphocyte count in patients with metastatic renal cell carcinoma receiving first-line combination immunotherapies: results from the International Metastatic Renal Cell Carcinoma Database Consortium
K Takemura, T Yuasa, A Lemelin, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
January 23, 2026
Broad beta-CoV immunity and transmission blockade by a single-dose live-attenuated vaccine with atypical codon usage
Nigeer Te, Alex Wing Hong Chin, Haogao Gu, et al.
International Journal of Cancer
|
December 31, 2024
Clinical outcomes by baseline metastases in patients with renal cell carcinoma treated with lenvatinib plus pembrolizumab versus sunitinib: Post hoc analysis of the CLEAR trial
Viktor Grünwald, Rana R McKay, Tomas Buchler, et al.
International Journal of Molecular Sciences
|
June 26, 2025
<i>HSD3B1</i> (c.1100C) Genotype Is Associated with Distinct Tumoral and Clinical Outcomes in Breast and Endometrial Cancers
Nikitha Vobugari, Allison Makovec, Samuel Kellen, et al.
The Journal of Clinical Investigation
|
April 23, 2024
Renal cell carcinoma histologic subtypes exhibit distinct transcriptional profiles
Pedro Barata, Shuchi Gulati, Andrew Elliott, et al.
Clinical Genitourinary Cancer
|
February 28, 2019
Neoadjuvant Sunitinib Decreases Inferior Vena Caval Thrombus Size and Is Associated With Improved Oncologic Outcomes: A Multicenter Comparative Analysis
Charles A Field, Brittney H Cotta, Juan Jimenez, et al.
Page
of 94
Search research articles
Search
Showing results (781-790 of 932) with videos related to
Sort By:
Page
of 94
JCO Precision Oncology
|
February 16, 2022
Biomarker-Based Phase II Study of Sapanisertib (TAK-228): An mTORC1/2 Inhibitor in Patients With Refractory Metastatic Renal Cell Carcinoma
Bradley A McGregor, Wanling Xie, Elio Adib, et al.
Journal of the American College of Cardiology
|
November 26, 2015
The National Cardiovascular Data Registry Voluntary Public Reporting Program: An Interim Report From the NCDR Public Reporting Advisory Group
Gregory J Dehmer, Jonathan Jennings, Ruth A Madden, et al.
Clinical Genitourinary Cancer
|
April 5, 2026
Outcomes of Complete Responders From First-line Therapy in Metastatic Renal Cell Carcinoma in the Real World: An Analysis From the International Metastatic Renal Cell Carcinoma Database Consortium
Martin Zarba, David Maj, Razane El Hajj Chehade, et al.
Frontiers in Oncology
|
May 20, 2026
International metastatic renal cell carcinoma database consortium classification and regression tree analysis to characterize objective response rates to first line in metastatic renal cell carcinoma
Martin Zarba, Dylan O'Sullivan, David Maj, et al.
ESMO Open
|
June 20, 2024
Prognostic significance of absolute lymphocyte count in patients with metastatic renal cell carcinoma receiving first-line combination immunotherapies: results from the International Metastatic Renal Cell Carcinoma Database Consortium
K Takemura, T Yuasa, A Lemelin, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
January 23, 2026
Broad beta-CoV immunity and transmission blockade by a single-dose live-attenuated vaccine with atypical codon usage
Nigeer Te, Alex Wing Hong Chin, Haogao Gu, et al.
International Journal of Cancer
|
December 31, 2024
Clinical outcomes by baseline metastases in patients with renal cell carcinoma treated with lenvatinib plus pembrolizumab versus sunitinib: Post hoc analysis of the CLEAR trial
Viktor Grünwald, Rana R McKay, Tomas Buchler, et al.
International Journal of Molecular Sciences
|
June 26, 2025
<i>HSD3B1</i> (c.1100C) Genotype Is Associated with Distinct Tumoral and Clinical Outcomes in Breast and Endometrial Cancers
Nikitha Vobugari, Allison Makovec, Samuel Kellen, et al.
The Journal of Clinical Investigation
|
April 23, 2024
Renal cell carcinoma histologic subtypes exhibit distinct transcriptional profiles
Pedro Barata, Shuchi Gulati, Andrew Elliott, et al.
Clinical Genitourinary Cancer
|
February 28, 2019
Neoadjuvant Sunitinib Decreases Inferior Vena Caval Thrombus Size and Is Associated With Improved Oncologic Outcomes: A Multicenter Comparative Analysis
Charles A Field, Brittney H Cotta, Juan Jimenez, et al.
Page
of 94